DiaMedica Q2 FY26 net loss widens to $10.14 million; R&D expenses climb to $8.15 million

Reuters2026/08/10 20:55

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

DiaMedica posted a Q2 net loss of USD 10.1 million, widening from USD 7.7 million a year earlier; loss per share was USD 0.19.
RD expense rose to USD 8.2 million from USD 5.8 million; GA edged up to USD 2.3 million from USD 2.2 million.
Cash, cash equivalents and investments fell to USD 43.5 million at June 30 from USD 59.9 million at year-end; runway forecast through 2027.
Phase 2 early-onset fetal growth restriction trial completed enrollment for its first cohort of 6 participants; topline results expected in September.
ReMEDy2 acute ischemic stroke trial enrollment topped 85% of the 200 participants needed for interim analysis, targeted for early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608101630BIZWIRE_USPR_____20260810_BW989621) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

DiaMedica Q2 FY26 net loss widens to $10.14 million; R&D expenses climb to $8.15 million

You may also like

Crypto prices